Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Acute Intermittent Porphyria Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The market for acute intermittent porphyria has experienced robust expansion in recent years. It is projected to increase from $4.66 billion in 2025 to $4.97 billion in 2026, at a compound annual growth rate (CAGR) of 6.5%. This historical expansion was driven by factors such as the restricted access to diagnostic facilities for AIP, insufficient public awareness of acute intermittent porphyria, a continued reliance on conventional treatment approaches, the development of hospital and clinic infrastructure, and an escalating demand for genetic testing.
The acute intermittent porphyria market is projected to experience robust expansion over the coming years. It is anticipated to reach $6.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This expansion during the forecast period is fueled by advancements in novel therapies and hematin formulations, the broadening of DNA and enzyme testing services, greater incorporation of telemedicine for rare conditions, increased awareness and educational initiatives for healthcare professionals, and the uptake of sophisticated monitoring and digital health instruments. Significant developments foreseen in this period encompass a rise in the adoption of genetic and enzyme-based diagnostic tests, heightened recognition of the importance of early diagnosis and management of AIP, an increase in prophylactic hematin infusions and targeted treatments, the growth of specialized treatment centers and research initiatives, and the incorporation of telemedicine alongside remote patient monitoring for individuals with AIP.
Get A Free Sample Report With In-Depth Market Insights:
Acute Intermittent Porphyria Market Growth Momentum: What Factors Are Shaping Demand?
The increasing occurrence of metabolic disorders is anticipated to boost the expansion of the acute intermittent porphyria market. These conditions involve irregularities in the body’s chemical reactions, interfering with typical metabolic functions. Genetic predisposition, lifestyle choices, environmental elements, and improved diagnostic capabilities are all factors contributing to the rising prevalence of metabolic disorders. This surge is prompting the pharmaceutical sector to allocate resources towards therapies for uncommon and inherited ailments, including acute intermittent porphyria. For instance, the Cleveland Clinic, a US-based nonprofit academic medical center, reported in December 2023 that inherited metabolic disorders collectively affect approximately 1 in 1,000 to 2,500 births worldwide. Consequently, the widespread presence of metabolic disorders is a key factor stimulating the growth of the acute intermittent porphyria market.
Acute Intermittent Porphyria Market Segment Landscape And Growth Outlook
The acute intermittent porphyria market covered in this report is segmented –
1) By Diagnosis: Urine Test, Blood Test, Serum Test, DNA Test, Other Diagnosis
2) By Treatment: Prophylactic Hematin Infusions, Gonadotropin-Releasing Hormone Analogues, Other Treatments
3) By End-Users: Hospitals And Clinics, Ambulatory Surgical Centers, Research Centers
Subsegments:
1) By Urine Test: Urine Porphobilinogen (PBG) Test, Urine Aminolevulinic Acid (ALA) Test, Urine Color Change Test
2) By Blood Test: Plasma Porphyrin Levels Test, Blood Aminolevulinic Acid (ALA) Test, Complete Blood Count (CBC) Test
3) By Serum Test: Serum Porphyrin Levels Test, Liver Function Test (LFT), Serum ALA and PBG Enzyme Test
4) By DNA Test: Genetic Mutation Testing, Gene Sequencing Test
5) By Other Diagnosis: Stool Test for Porphyrins, Imaging Tests (CT/MRI Scans for Complications), Enzyme Activity Assays.
Acute Intermittent Porphyria Market Trends Redefining Industry Growth
Major companies within the acute intermittent porphyria market are concentrating on developing innovative products, such as acute intermittent porphyria management tablets, to better serve customers requiring advanced features. Acute intermittent porphyria management tablets refer to oral medications utilized to manage or prevent the symptoms and acute attacks associated with AIP. For instance, in October 2023, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, announced the US Food & Drug Administration (USFDA) approval for its Chlorpromazine Hydrochloride Tablets USP, available in strengths of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg. Chlorpromazine hydrochloride tablets USP, in doses of 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, are employed to manage the symptoms of psychotic disorders and treat schizophrenia. They also help control nausea and vomiting, alleviate restlessness and apprehension before surgery, and serve as an adjunct in treating tetanus. Additionally, these tablets are utilized in the management of acute intermittent porphyria, to control manic symptoms of manic-depressive illness, and to provide relief from intractable hiccups.
Acute Intermittent Porphyria Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the acute intermittent porphyria market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Vertex Pharmaceuticals Inc., Eisai Co. Ltd., Octapharma AG, BioMarin Pharmaceutical Inc., Swedish Orphan Biovitrum AB, Alnylam Pharmaceuticals Inc., Mylan N.V., Clinuvel Pharmaceuticals Ltd., Recordati Rare Diseases Inc.
View The Full Acute Intermittent Porphyria Market Report:
Acute Intermittent Porphyria Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the acute intermittent porphyria market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute intermittent porphyria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
